← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Advantagene, Inc
Auburndale, MA
$13,708,660
Total funding
7
Grants
Funding over time
peak $2M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$13,708,660 · 7
By mechanism
R44$12,422,406 · 3
R43$1,286,254 · 4
Investigators at Advantagene, Inc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer$1,917,582
R44 · FY2012 · CA
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer$1,902,504
R44 · FY2011 · CA
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer$1,857,725
R44 · FY2013 · CA
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer$1,473,388
R44 · FY2009 · CA
Clinical study of AdV-tk radiogene therapy for malignant glioma$794,415
R44 · FY2008 · CA
Clinical study of AdV-tk radiogene therapy for malignant glioma$788,188
R44 · FY2007 · CA
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$659,516
R44 · FY2018 · CA
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$611,350
R44 · FY2020 · CA
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$611,350
R44 · FY2021 · CA
Clinical study of AdV-tk radiogene therapy for malignant glioma$510,001
R44 · FY2009 · CA
Clinical study of AdV-tk radiogenetherapy for malignant*$402,041
R44 · FY2005 · CA
Clinical study of AdV-tk radiogene therapy for glioma$376,831
R44 · FY2004 · CA
Clinical study of GMCI in Pancreatic Cancer$376,666
R43 · FY2007 · CA
Clinical study of GMCI in Pancreatic Cancer$370,718
R43 · FY2006 · CA
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$299,985
R44 · FY2016 · CA
Clinically suitable approach for gene-mediated therapy of cirrhosis.$224,999
R43 · FY2014 · AA
Improved system for producing adenoviral vectors$213,871
R43 · FY2007 · CA
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$116,400
R44 · FY2019 · CA
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer$101,130
R44 · FY2007 · CA
Combination of GM-CSF with TKR gene therapy$100,000
R43 · FY2003 · CA